Literature DB >> 29169744

The neuropathology of multiple system atrophy and its therapeutic implications.

Elvira Valera1, Eliezer Masliah2.   

Abstract

Multiple system atrophy (MSA) is a fatal neurodegenerative disorder characterized by the abnormal accumulation of toxic forms of the synaptic protein alpha-synuclein (α-syn) within oligodendrocytes and neurons. The presence of α-syn within oligodendrocytes in the form of glial cytoplasmic inclusions is the diagnostic hallmark of MSA. However, it has been postulated that α-syn is produced in neurons and propagates to oligodendrocytes, where unknown mechanisms lead to its accumulation. The presence of α-syn within neurons in MSA has not been so extensively studied, but it may shed light into neuropathological mechanisms leading to oligodendroglial accumulation. Here we summarize the principal neuropathological events of MSA, and discuss how a deeper knowledge of these mechanisms may help develop effective therapies targeting α-syn accumulation and spreading.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29169744      PMCID: PMC5954415          DOI: 10.1016/j.autneu.2017.11.002

Source DB:  PubMed          Journal:  Auton Neurosci        ISSN: 1566-0702            Impact factor:   3.145


  101 in total

1.  Activation of the unfolded protein response in Parkinson's disease.

Authors:  J J M Hoozemans; E S van Haastert; P Eikelenboom; R A I de Vos; J M Rozemuller; W Scheper
Journal:  Biochem Biophys Res Commun       Date:  2007-01-17       Impact factor: 3.575

2.  Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein.

Authors:  He-Jin Lee; Ji-Eun Suk; Eun-Jin Bae; Jung-Ho Lee; Seung R Paik; Seung-Jae Lee
Journal:  Int J Biochem Cell Biol       Date:  2008-01-20       Impact factor: 5.085

3.  Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes.

Authors:  Philipp J Kahle; Manuela Neumann; Laurence Ozmen; Veronika Muller; Helmut Jacobsen; Will Spooren; Babette Fuss; Barbara Mallon; Wendy B Macklin; Hideo Fujiwara; Masato Hasegawa; Takeshi Iwatsubo; Hans A Kretzschmar; Christian Haass
Journal:  EMBO Rep       Date:  2002-05-24       Impact factor: 8.807

Review 4.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

5.  Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.

Authors:  Markus Mandler; Elvira Valera; Edward Rockenstein; Harald Weninger; Christina Patrick; Anthony Adame; Radmila Santic; Stefanie Meindl; Benjamin Vigl; Oskar Smrzka; Achim Schneeberger; Frank Mattner; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2014-02-14       Impact factor: 17.088

6.  Suppression of dynamin GTPase decreases α-synuclein uptake by neuronal and oligodendroglial cells: a potent therapeutic target for synucleinopathy.

Authors:  Masatoshi Konno; Takafumi Hasegawa; Toru Baba; Emiko Miura; Naoto Sugeno; Akio Kikuchi; Fabienne C Fiesel; Tsutomu Sasaki; Masashi Aoki; Yasuto Itoyama; Atsushi Takeda
Journal:  Mol Neurodegener       Date:  2012-08-14       Impact factor: 14.195

Review 7.  Animal models of multiple system atrophy.

Authors:  Nadia Stefanova; Gregor K Wenning
Journal:  Clin Auton Res       Date:  2015-01-14       Impact factor: 4.435

8.  Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease.

Authors:  Elvira Valera; Michael Mante; Scott Anderson; Edward Rockenstein; Eliezer Masliah
Journal:  J Neuroinflammation       Date:  2015-05-14       Impact factor: 8.322

Review 9.  Review: Multiple system atrophy: emerging targets for interventional therapies.

Authors:  N Stefanova; G K Wenning
Journal:  Neuropathol Appl Neurobiol       Date:  2016-02       Impact factor: 8.090

10.  Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy.

Authors:  Elvira Valera; Brian Spencer; Jerel A Fields; Ivy Trinh; Anthony Adame; Michael Mante; Edward Rockenstein; Paula Desplats; Eliezer Masliah
Journal:  Acta Neuropathol Commun       Date:  2017-01-05       Impact factor: 7.801

View more
  15 in total

1.  Cognitive impairment and structural brain damage in multiple system atrophy-parkinsonian variant.

Authors:  Francesca Caso; Elisa Canu; Milica Jecmenica Lukic; Igor N Petrovic; Andrea Fontana; Ivan Nikolic; Vladimir S Kostic; Massimo Filippi; Federica Agosta
Journal:  J Neurol       Date:  2019-09-26       Impact factor: 4.849

2.  Frequency and factors related to drooling in Chinese patients with multiple system atrophy: a cross-sectional study.

Authors:  Yalan Chen; Hongyan Huang; Pingping Ning; Quanzhen Zhao; Hui Wang; Qiuyan Shen; Yanming Xu
Journal:  Clin Auton Res       Date:  2019-03-12       Impact factor: 4.435

3.  Investigating ELOVL7 coding variants in multiple system atrophy.

Authors:  Anna I Wernick; Ronald L Walton; Alexandra I Soto-Beasley; Shunsuke Koga; Yingxue Ren; Michael G Heckman; Lukasz M Milanowski; Rebecca R Valentino; Naveen Kondru; Ryan J Uitti; William P Cheshire; Zbigniew K Wszolek; Dennis W Dickson; Owen A Ross
Journal:  Neurosci Lett       Date:  2021-02-15       Impact factor: 3.046

4.  Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies.

Authors:  Marie-Laure Arotcarena; Mathieu Bourdenx; Nathalie Dutheil; Marie-Laure Thiolat; Evelyne Doudnikoff; Sandra Dovero; Andrea Ballabio; Pierre-Olivier Fernagut; Wassilios G Meissner; Erwan Bezard; Benjamin Dehay
Journal:  JCI Insight       Date:  2019-08-22

Review 5.  Selective vulnerability in α-synucleinopathies.

Authors:  Javier Alegre-Abarrategui; Katherine R Brimblecombe; Rosalind F Roberts; Elisavet Velentza-Almpani; Bension S Tilley; Nora Bengoa-Vergniory; Christos Proukakis
Journal:  Acta Neuropathol       Date:  2019-04-20       Impact factor: 17.088

6.  PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes.

Authors:  Sonja Schönecker; Matthias Brendel; Carla Palleis; Leonie Beyer; Günter U Höglinger; Elisabeth Schuh; Boris-Stephan Rauchmann; Julia Sauerbeck; Guido Rohrer; Stefan Sonnenfeld; Katsutoshi Furukawa; Aiko Ishiki; Nobuyuki Okamura; Peter Bartenstein; Marianne Dieterich; Kai Bötzel; Adrian Danek; Axel Rominger; Johannes Levin
Journal:  Front Aging Neurosci       Date:  2019-09-11       Impact factor: 5.750

Review 7.  Models of multiple system atrophy.

Authors:  Diadem Ricarte; Darlene Ortiz; He-Jin Lee; Seung-Jae Lee
Journal:  Exp Mol Med       Date:  2019-11-18       Impact factor: 8.718

Review 8.  Insights into the pathogenesis of multiple system atrophy: focus on glial cytoplasmic inclusions.

Authors:  Seiji Kaji; Takakuni Maki; Tomoyuki Ishimoto; Hodaka Yamakado; Ryosuke Takahashi
Journal:  Transl Neurodegener       Date:  2020-02-17       Impact factor: 8.014

9.  Increased expression of myelin-associated genes in frontal cortex of SNCA overexpressing rats and Parkinson's disease patients.

Authors:  Thomas Hentrich; Zinah Wassouf; Christine Ehrhardt; Eva Haas; James D Mills; Eleonora Aronica; Tiago Fleming Outeiro; Jeannette Hübener-Schmid; Olaf Riess; Nicolas Casadei; Julia M Schulze-Hentrich
Journal:  Aging (Albany NY)       Date:  2020-10-05       Impact factor: 5.682

10.  Signs of early cellular dysfunction in multiple system atrophy.

Authors:  M Herrera-Vaquero; A Heras-Garvin; F Krismer; R Deleanu; S Boesch; G K Wenning; N Stefanova
Journal:  Neuropathol Appl Neurobiol       Date:  2020-09-17       Impact factor: 8.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.